Based on these studies, the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation recommends post-transplant maintenance therapy with a FLT3 inhibitor, preferably sorafenib, for patients who undergo allo-HCT for FLT3-ITD-mutated AML [57]. The gene discussed is FLT3; the disease is acute myeloid leukemia.